National Health (Listed drugs on F1 or F2) Amendment Determination 2022 (No. 8) (Cth)

PB 95 of 2022

National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 8)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following determination.

Dated               29 September 2022                 

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)                2

1  Name

This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 8).

This instrument may also be cited as PB 95 of 2022.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 October 2022.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1. Schedule 1, after item dealing with Darolutamide

insert:

Decitabine with cedazuridine

1. Schedule 1, after item dealing with Encorafenib

omit:

Enfuvirtide                

1. Schedule 1, after item dealing with Magnesium

insert:

Mecasermin  

1. Schedule 1, after item dealing with Pizotifen

Omit:

Plerixafor

1. Schedule 1, after item dealing with Polyethylene Glycol 400 with Propylene Glycol

Omit:

Pomalidomide

1. Schedule 1, after item dealing with Sofosbuvir with velpatasvir

insert:

Somatrogon

1. Schedule 1, after item dealing with Travoprost

insert:

Trientine

1. Schedule 2, after item dealing with Alendronic acid with colecalciferol

omit:

Alendronic acid with colecalciferol and calcium

1. Schedule 2, after item dealing with Piroxicam

insert:

Plerixafor

10Schedule 2, after item dealing with Polyvinyl alcohol

insert:

Pomalidomide